Table 1 Characteristics of the Study Population
From: Clinical phenotyping in sarcoidosis using cluster analysis
Characteristic | Missing: N (%) | N = 5541 |
|---|---|---|
Gender | ||
 Male | 0 (0.0) | 265 (47.8%) |
 Female | 289 (52.2%) | |
Race | ||
 White | 12 (2.2) | 443 (81.7%) |
 Black | 90 (16.6%) | |
 Asian | 4 (0.7%) | |
 American Indian | 2 (0.4%) | |
 Other | 3 (0.6%) | |
Smoking status | ||
 Never smoker | 2 (0.4) | 367 (66.5%) |
 Ever smoker | 185 (33.5%) | |
Lungs | 0 (0.0) | 534 (96.4%) |
Cardiac | 0 (0.0) | 71 (12.8%) |
Skin | 0 (0.0) | 68 (12.3%) |
Eye | 0 (0.0) | 58 (10.5%) |
Calcium/Vit D Metabolism | 0 (0.0) | 54 (9.7%) |
Liver | 0 (0.0) | 40 (7.2%) |
Extrathoracic lymph nodes | 0 (0.0) | 35 (6.3%) |
Bone-Joint | 0 (0.0) | 19 (3.4%) |
Spleen | 0 (0.0) | 19 (3.4%) |
Lofgren’s | 0 (0.0) | 17 (3.1%) |
Other organs | 0 (0.0) | 17 (3.1%) |
Neuro | 0 (0.0) | 14 (2.5%) |
ENT | 0 (0.0) | 12 (2.2%) |
Kidney | 0 (0.0) | 9 (1.6%) |
Muscle | 0 (0.0) | 7 (1.3%) |
Parotid salivary | 0 (0.0) | 5 (0.9%) |
Bone marrow | 0 (0.0) | 5 (0.9%) |
Extrapulmonary involvement | 0 (0.0) | 259 (46.8%) |
Ever treatment | 104 (18.8) | 310 (68.9%) |
Scadding stage | ||
 0 | 44 (7.9) | 102 (20.0%) |
 1 | 67 (13.1%) | |
 2 | 183 (35.9%) | |
 3 | 86 (16.9%) | |
 4 | 72 (14.1%) | |
Number of organs involved | ||
 0 | 0 (0.0) | 10 (1.8%) |
 1 | 303 (54.7%) | |
 2 | 149 (26.9%) | |
 3 | 53 (9.6%) | |
 4 | 24 (4.3%) | |
 5 | 14 (2.5%) | |
 6 | 1 (0.2%) | |
Mean number of organs | 0 (0.0) | 1.7 (1.0) |
BMI | 0 (0.0) | 30.5 (6.8) |
Age at diagnosis | 1 (0.2) | 46.6 (10.9) |
Duration of Disease | 1 (0.2) | 6.0 (7.1) |
FEV1/FVC | 0 (0.0) | 74.9 (9.8) |
FVCpp | 0 (0.0) | 86.7 (16.8) |
FEV1pp | 0 (0.0) | 83.2 (19.4) |